GSK (LON:GSK) Given New GBX 1,500 Price Target at JPMorgan Chase & Co.

GSK (LON:GSK) had its price objective lifted by investment analysts at JPMorgan Chase & Co. from GBX 1,400 to GBX 1,500 in a report issued on Friday, MarketBeat.com reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential downside of 15.18% from the company’s current price.

A number of other research analysts have also weighed in on GSK. Shore Capital reissued a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a research note on Monday, October 20th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,450 price objective on shares of GSK in a research note on Thursday, July 31st. Jefferies Financial Group boosted their price target on shares of GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a research report on Monday. Finally, Berenberg Bank reaffirmed a “hold” rating and set a GBX 1,600 price target on shares of GSK in a research report on Friday, July 18th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of GBX 1,750.

GSK Price Performance

GSK stock traded down GBX 10 during midday trading on Friday, reaching GBX 1,768.50. The stock had a trading volume of 7,021,667 shares, compared to its average volume of 11,714,042. GSK has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 1,799. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The company’s fifty day simple moving average is GBX 1,584.45 and its 200 day simple moving average is GBX 1,480.94. The company has a market cap of £71.08 billion, a price-to-earnings ratio of 13.30, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its earnings results on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, sell-side analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GSK news, insider Wendy Becker bought 526 shares of the business’s stock in a transaction that occurred on Friday, September 19th. The shares were purchased at an average cost of GBX 1,503 per share, with a total value of £7,905.78. Over the last quarter, insiders have purchased 576 shares of company stock worth $865,799. 0.20% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.